clinical trial · NCT04240886
Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds
Basilea Pharmaceutica·phase2·terminated·n = 21
Invasive Fungal Infectionsfosmanogepix
brief summary
This is a Phase 2, multicenter study to evaluate APX001 for the treatment of invasive fungal infections caused by Aspergillus spp. or rare molds (eg, Scedosporium spp., Fusarium spp., and Mucorales fungi).
started
Jan 4, 2020
primary completion
Mar 29, 2022
completion
May 9, 2022
last updated
Sep 16, 2025
official title
A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of APX001 in the Treatment of Patients With Invasive Mold Infections Caused by Aspergillus Species or Rare Molds
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol